AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00151203
Drug: Clarithromycin, Lenalidomide, Dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each subsequent cycle.~Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day beginning on day 2 of cycle 1.~Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles.
Trial: NCT01205997
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
Trial: NCT02346890
Drug: AZD1722
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01077375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.~* Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period.
Trial: NCT03725436
Drug: MDM2/MDMX Inhibitor ALRN-6924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02793648
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner
Trial: NCT02793648
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner
Trial: NCT02637284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-03 (placebo) as a control group.~Phase 1b: All subjects will take 3 tablets of PCO-03 (placebo) every 8 hours during two weeks, as a control group.
Trial: NCT01064830
Drug: vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
Trial: NCT03720392
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
Trial: NCT03725267
Drug: Melatonin Pill
RxNorm normalized name: melatonin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 1 pill of melatonin each day during polymyxin B therapy for a maximum of 14 days.
Trial: NCT03725267
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 1 pill of placebo each day during polymyxin B therapy for a maximum of 14 days.
Trial: NCT02700087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with symptomatic laryngomalacia who meet inclusion criteria will be randomized to receive placebo, ranitidine or famotidine, in order to see if these medications help their symptoms to resolve.
Trial: NCT04581824
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.
Trial: NCT01205997
Drug: placebo(distilled water)
RxNorm normalized name: petroleum distillate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
Trial: NCT02560363
Drug: AZD9977 immediate release (IR) oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose
Trial: NCT02560363
Drug: AZD9977 extended release (ER) capsules [fast]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg (2 x 60mg capsules) single dose
Trial: NCT02560363
Drug: AZD9977 extended release (ER) capsules [intermediate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg (2 x 60mg capsules) single dose
Trial: NCT02560363
Drug: AZD9977 extended release (ER) capsules [slow]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg (2 x 60mg capsules) single dose
Trial: NCT02292966
Drug: DCV/ASV/BCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.
Trial: NCT00593580
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02948101
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02013453
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by infusion.
Trial: NCT03201913
Drug: TTC-352
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.
Trial: NCT03612856
Drug: AB023- Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of 0.25 mg/kg AB023.
Trial: NCT03612856
Drug: AB023-Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of 0.5 mg/kg AB023.
Trial: NCT03612856
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of placebo.
Trial: NCT01513200
Drug: Bendavia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours
Trial: NCT01606878
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01606878
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02780323
Drug: CELBESTA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
Trial: NCT02780323
Drug: CELEBREX®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
Trial: NCT02780323
Drug: CELEBREX® placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
Trial: NCT02780323
Drug: CELBESTA® placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
Trial: NCT00586664
Drug: Bepreve (bepotastine besilate ophthalmic solution) 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT00586664
Drug: placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT04173793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT01439815
Drug: Saline Nasal Spray
RxNorm normalized name: Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two sprays in each nostril once daily
Trial: NCT02069340
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00591526
Drug: Arac
RxNorm normalized name: Carac
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ommit ARAC in the chemotherapy
Trial: NCT00003673
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00861731
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvasatin therapy alone at the dose of 40 mg/day
Trial: NCT00861731
Drug: EZE/simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE/simvastatin combined therapy at the dose of 10/20 mg/day
Trial: NCT00861731
Drug: EZE/simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE/simvastatin combined therapy at the dose of 10/40 mg/day
Trial: NCT02354352
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.
Trial: NCT02354352
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
Trial: NCT04442178
Drug: CYT107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Trial: NCT04442178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Trial: NCT01496937
Drug: GLPG0974
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00791154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered with Carboplatin and Etoposide
Trial: NCT02232880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
Trial: NCT03603405
Drug: ADV/HSV-tk (gene therapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
Trial: NCT00795483
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic Acid 5mg/year
Trial: NCT00795483
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5mg/2years)
Trial: NCT02848443
Drug: Trifluridine/tipiracil hydrochloride (S 95005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
Trial: NCT00266864
Drug: Testosterone Transdermal System (Androderm 5 mg patch)
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone Transdermal System (Androderm 5 mg patch)
Trial: NCT04616079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching single dose of REGN6490
Trial: NCT03739996
Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTIs will not be provided by the study. Participants will obtain NRTIs outside of the study through routine care.
Trial: NCT02338336
Drug: Nowarta110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.
Trial: NCT02338336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo liquid for topic administration.
Trial: NCT04057118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, twice per day
Trial: NCT01302132
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT00729222
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rolofylline placebo IV infusion over 4 hours.
Trial: NCT02850081
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment (one of four):~* Simvastatin (to 40mg without amlodipine)~* Simvastatin (to 20 mg if currently on amlodipine)~* Atorvastatin (to 80mg)~* Rosuvastatin (to 20mg)
Trial: NCT00627146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 days
Trial: NCT01145638
Drug: iron sulphate
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, 200 mg per day (100 mg bid),12 weeks
Trial: NCT00789074
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1mg BD
Trial: NCT01490398
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is \> 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
Trial: NCT01407003
Drug: LIK066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single or multiple doses of LIK066
Trial: NCT01407003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single or multiple doses of a matching placebo
Trial: NCT04531462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04590742
Drug: melatonin 6mg
RxNorm normalized name: melatonin 6 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 weeks of melatonin (6mg) given to patient
Trial: NCT00905684
Drug: EE30/DRSP (Yasmin, BAY86-5131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients under regular daily life treatment receiving Yasmin according to local drug information
Trial: NCT00905684
Drug: Any other OC
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients under regular daily life treatment receiving any other OC according to local drug information
Trial: NCT02740972
Drug: NS-065/NCNP-01
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04437160
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600mg/m2 IV, q21d\*4cycls
Trial: NCT01172405
Drug: Ibuprofen plus caffeine
RxNorm normalized name: caffeine / ergotamine / ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
Trial: NCT01172405
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One or two tablets of ibuprofen 400 mg when presenting headache.
Trial: NCT04590742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient given 6 weeks of placebo tablet
Trial: NCT04048304
Drug: duration of standard antibiotic therapy
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
Trial: NCT02292784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product
Trial: NCT03603366
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.
Trial: NCT02815189
Drug: Acetaminophen 325 mg for Flare up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will be evaluated a week after completion the clinical procedures.
Trial: NCT03856658
Drug: Heparinized Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
Trial: NCT00559494
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
Trial: NCT00559494
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 250cc via central line similar to minocycline arm administration protocol
Trial: NCT01659554
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (25 mg flat dose) prepared in 500 ml dialysis fluid (glucose or icodextrin-based).
Trial: NCT00821444
Drug: B16 Fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg tablet, single dose X 3
Trial: NCT01850108
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days 6 and 5 before BMT: 14.5mg/kg IV; Days 3 and 4 after BMT: 50mg/kg/day
Trial: NCT01413932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD oral dosing
Trial: NCT00870103
Drug: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop every 6 hours into the study eye
Trial: NCT04161339
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amido pills/daily for 8 weeks
Trial: NCT03699475
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GVHD prophylaxis
Trial: NCT00539760
Drug: GSK1827771
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1827771 will be administered using injection via subcutaneous (SC) route.
Trial: NCT00539760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to GSK1827771 for Injection will be administered via SC route
Trial: NCT03932006
Drug: Fengshigutong Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fengshigutong Capsule 1.2g twice a day,orally
Trial: NCT00157040
Drug: Antihemophilic factor, recombinant, manufactured protein-free
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06177574
Drug: BIC/FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEST and TREAT strategy: Study group will start the intervention at the first visit with their healthcare provider.
Trial: NCT00052351
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00052351
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no